Dr. Ananworanich most recently led influenza vaccine development at Moderna and brings more than 20 years of clinical and industry experience in infectious disease
LEIDEN, The Netherlands - September 12, 2024 - Leyden Laboratories B.V. (the "Company" or "Leyden Labs"), a biotechnology company working to free people from the threat of respiratory viruses by boosting mucosal immunity, today announced the appointment of Jintanat Ananworanich, M.D., Ph.D., as chief medical officer.
"We are very excited to announce the appointment of Dr. Ananworanich as the CMO of Leyden Labs," said Koenraad Wiedhaup, co-founder and CEO of Leyden Labs.
To her role at Leyden Labs, Dr. Ananworanich brings more than 20 years of experience in infectious disease, most recently serving as Executive Director of clinical development at Moderna where she focused on influenza vaccine development programs. Prior to her time at Moderna, Dr. Ananworanich was Clinical Development Leader at the Bill and Melinda Gates Medical Research Institute.
Dr. Ananworanich commented, "I am honored to join Leyden Labs, a company at the forefront of employing the power of mucosal immunity to protect against known and unknown respiratory viruses."
Dr. Jaap Goudsmit, co-founder and CSO of Leyden Labs commented, "Dr. Ananworanich brings impressive breadth and immense depth in both clinical and development experience."
Dr. Ananworanich received her medical degree from Prince of Songkhla University in Thailand, and completed her PhD with research on antiretroviral treatments for HIV at the University of Amsterdam. She currently serves as Professor of Internal Medicine in the Department of Global Health at The University of Amsterdam.
About Leyden Laboratories B.V.
To learn more, visit www.leydenlabs.com.
Corporate Contact: Leyden Laboratories B.V., investors@leydenlabs.com
Media Contact: Megan Prock McGrath, CTD Comms, LLC, media@leydenlabs.com
Forward-looking statements: This press release contains forward-looking statements, which involve certain risks and uncertainties related to the mechanism of action, profile, and timing of clinical trials of CR9114. Leyden Labs' actual results and achievements may materially differ from those predicted by the forward-looking statements as a result of various factors.
